Skip to main content

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in March:

TD Cowen 46th Annual Health Care Conference in Boston, MA
Date: Monday, March 2, 2026
Company Presentation: 10:30 am EST
Management to participate in one-on-one meetings throughout the conference

Jefferies Biotech on the Beach Summit in Miami, FL
Date: Tuesday, March 10, 2026
Management to participate in one-on-one meetings throughout the conference

Barclays 28th Annual Global Healthcare Conference in Miami, FL
Date: Wednesday, March 11, 2026
Fireside Chat: 3:30 pm EDT
Management to participate in one-on-one meetings throughout the conference

To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  250.56
+0.00 (0.00%)
AAPL  270.23
+0.00 (0.00%)
AMD  278.39
+0.00 (0.00%)
BAC  53.91
+0.00 (0.00%)
GOOG  339.40
+0.00 (0.00%)
META  688.55
+0.00 (0.00%)
MSFT  422.79
+0.00 (0.00%)
NVDA  201.68
+0.00 (0.00%)
ORCL  175.06
+0.00 (0.00%)
TSLA  400.62
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.